RE:RE:RE:Pump and dump Holy smokes, in 1st line, it should read "they could".... probably by 2023/24 or sooner if someone liked the safety results of phase 1
stockbuphoon wrote: Hey James,
I believe that they couldn't partner/ sell each small molecule indication in kidney, lung, heart, liver for lots of money once they have completed phase 1 or phase 2. Low dosages produced efficacy in all of these organs over 5 years and improved patients in Alstrom disease which was impressive. Now, they're tripling the dosage. Some had called 4050 "penicillin" and it "apparently" had MANY suitors in summer of 2018. SALP observed as PLi negotiated themselves out of a deal and then wielded their majority strength to hammer the recap through. They have slowly done little on 4050 while wasting time and money selling off Plasma division. Why would Liminal go so slowly with a drug that shows incredible promise? That's the question and many old shareholders are demanding an answer.
james700 wrote:
Look no further than July 1st and July 4th of 2020, for the artificial rise in stock price, actually exceeded $30+. Lucky a friend told me and I was able to sell my $15 shares for about $22 and got most of the extra money I threw in to be part of the new company LMNL. Unfortunately, the plan is not to build anything but rather dismantle and hope that retail buy up the remaining $150M worth of PAPER they are offering... WHO BELIEVES THAT THE SMALL MOLECULE BUSINESS WILL GENERATE PROFIT ANYTIME IN THE NEXT 2-5 YEARS????